Evidence map›Paper›PMID 36924501›Full record

ArticleCell reports2023

Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.

Bhavna Hora, Hui Li, Xiaoying Shen, Mitchell Martin, Yue Chen, Madison Berry, Tyler Evangelous, Andrew N Macintyre, Aria Arus-Altuz, Shuyi Wang and 16 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 1 country.

Bhavna HoraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Hui LiDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Xiaoying ShenDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Mitchell MartinDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Yue ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Madison BerryDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Tyler EvangelousDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Andrew N MacintyreDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Aria Arus-AltuzDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Shuyi WangDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ajay SinghDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Chengyan ZhaoDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Nicole De NaeyerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Todd DeMarcoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Cindy KuykendallDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Thaddeus GurleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.
Thomas DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
John MisamoreBIOQUAL, Inc., Rockville, MD 20850, USA.
Mark G LewisBIOQUAL, Inc., Rockville, MD 20850, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
George M ShawDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu.
Duke University · USUniversity of Pennsylvania · USBioqual · US

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kshitij Wagh · 2017 to 2026
$40.7M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesR01AI165080 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2021 to 2026
$6.6M
HIV-1 gp140 Oligomers as Vaccine ImmunogensP01AI048280 · NIAID · The Johns Hopkins University · PI QUINNAN, GERALD V. · 2001 to 2003
$4.6M
Neonatal Immunity to novel TF SHIVsR01AI140897 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, WILTON B · 2018 to 2022
$4.4M
Project 3: Targeting Neurokinin 1 ReceptorP01MH105303 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI RAPPAPORT, JAY · 2014 to 2017
$4.3M
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2M
Neonatal Immunity to novel TF SHIVsR37AI140897 · NIAID · DUKE UNIVERSITY · PI Wilton B Williams · 2024 to 2026
$2.4M
NIAID NIH HHS HHSN272201800004CNIAID NIH HHS P01 AI048280NIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI140897NIAID NIH HHS R01 AI160607NIAID NIH HHS R01 AI165080NIAID NIH HHS R37 AI140897NIAID NIH HHS UC6 AI058607NIMH NIH HHS P01 MH105303
6 · The paper itself

Abstract

Infants and children infected with human immunodeficiency virus (HIV)-1 have been shown to develop neutralizing antibodies (nAbs) against heterologous HIV-1 strains, characteristic of broadly nAbs (bnAbs). Thus, having a neonatal model for the induction of heterologous HIV-1 nAbs may provide insights into the mechanisms of neonatal bnAb development. Here, we describe a neonatal model for heterologous HIV-1 nAb induction in pathogenic simian-HIV (SHIV)-infected rhesus macaques (RMs). Viral envelope (env) evolution showed mutations at multiple sites, including nAb epitopes. All 13 RMs generated plasma autologous HIV-1 nAbs. However, 8/13 (62%) RMs generated heterologous HIV-1 nAbs with increasing potency over time, albeit with limited breadth, and mapped to multiple nAb epitopes, suggestive of a polyclonal response. Moreover, plasma heterologous HIV-1 nAb development was associated with antigen-specific, lymph-node-derived germinal center activity. We define a neonatal model for heterologous HIV-1 nAb induction that may inform future pediatric HIV-1 vaccines for bnAb induction in infants and children.

Indexed as

Communicable DiseasesHIV-1HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAntibodies, NeutralizingBroadly Neutralizing AntibodiesChildEpitopesHIV AntibodiesHumansInfantInfant, NewbornMacaca mulattaAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHIV Antibodiesautologous SHIV NAbsCP: Immunologygerminal center activityHIV-1 env evolutionHIV-1 Env glycosylationneonatal heterologous NAbsneonatal immunityneonatal SHIV infectiontranscriptomics

Identifiers

PMID36924501
PMCPMC10117998
OpenAlexW4324134890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.